SAB Biotherapeutics, Inc. (SABS), a clinical-stage biopharmaceutical company, has made significant progress with its lead immunotherapy candidate, SAB-142, in the treatment of Type 1 Diabetes (T1D).
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), is being developed as a disease-modifying treatment aimed at delaying or preventing the progression of T1D.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com